A detailed history of Nisa Investment Advisors, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 66,240 shares of RYTM stock, worth $3.97 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
66,240
Previous 374,347 82.31%
Holding current value
$3.97 Million
Previous $15.4 Million 77.42%
% of portfolio
0.02%
Previous 0.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$40.81 - $55.0 $12.6 Million - $16.9 Million
-308,107 Reduced 82.31%
66,240 $3.47 Million
Q2 2024

Jul 19, 2024

BUY
$35.41 - $44.37 $8.11 Million - $10.2 Million
229,056 Added 157.65%
374,347 $15.4 Million
Q1 2024

May 01, 2024

BUY
$39.12 - $52.44 $5.63 Million - $7.55 Million
144,035 Added 11467.75%
145,291 $6.3 Million
Q4 2023

Jan 25, 2024

BUY
$21.39 - $49.64 $12,834 - $29,784
600 Added 91.46%
1,256 $57,000
Q3 2023

Nov 02, 2023

BUY
$15.81 - $27.8 $9,802 - $17,236
620 Added 1722.22%
656 $15,000
Q2 2023

Aug 11, 2023

BUY
$16.32 - $21.15 $587 - $761
36 New
36 $0
Q2 2022

Aug 03, 2022

SELL
$3.12 - $12.25 $73,008 - $286,650
-23,400 Closed
0 $0
Q1 2022

Apr 29, 2022

BUY
$6.13 - $12.24 $121,374 - $242,352
19,800 Added 550.0%
23,400 $270,000
Q4 2021

Feb 03, 2022

BUY
$8.62 - $13.9 $26,290 - $42,395
3,050 Added 554.55%
3,600 $27,000
Q4 2020

Jan 25, 2021

SELL
$21.17 - $32.61 $28,579 - $44,023
-1,350 Reduced 71.05%
550 $16,000
Q3 2020

Oct 20, 2020

BUY
$18.13 - $30.61 $34,447 - $58,159
1,900 New
1,900 $41,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.34B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.